Stephen Liu: Final anaysis of WJOG9717L

Final analysis data and exploratory biomarker analysis of a randomized phase II study of osimertinib plus bevacizumab versus osimertinib monotherapy for untreated patients with non-squamous non-small-cell lung cancer harboring EGFRmutations: the WJOG9717L study.

Authors: Hirotsugu Kenmotsu, Kazuko Sakai, Keita Mori, Terufumi Kato, Shunichi Sugawara, Keisuke Kirita, Yasuto Yoneshima, Koichi Azuma, Kazumi Nishino, Shunsuke Teraoka, Ryo Koyama, Ken Masuda, Hidetoshi Hayashi, Ryo Toyozawa, Satoru Miura, Yuki Sato, Kazuhiko Nakagawa, Nobuyuki Yamamoto, Kazuto Nishio, and  Takahashi.

Stephen Liu is an Associate Professor of Medicine at Georgetown University, where he holds the positions of Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center.

As a board-certified medical oncologist specializing in lung cancer and drug development, Dr. Liu is known for his expertise in advanced thoracic malignancies. His research focuses on novel therapeutic agents and innovative combinations to improve treatment outcomes for patients with lung cancer.

Dr. Liu has received multiple teaching awards and actively engages in post-graduate education initiatives. Furthermore, he co-hosts the official podcast of the International Association for the Study of Lung Cancer (IASLC), “Lung Cancer Considered”.